염증성장질환의 치료: 새로운 약제를 중심으로

Title
염증성장질환의 치료: 새로운 약제를 중심으로
Other Titles
Emerging Drugs in the Treatment of Inflammatory Bowel Disease: Beyond Anti-TNF-α
Author(s)
장병익김경옥
Keywords
Inflammatory bowel disease; Therapeutics; Infliximab; Biological products
Issue Date
201111
Publisher
대한소화기학회
Citation
대한소화기학회지, v.58, no.5, pp.235 - 244
Abstract
Understanding of the pathophysiology of inflammatory bowel disease (IBD) is constantly evolving and, recently, a number of biologic agents have been developed. They selectively target specific molecule or pathways and correct the imbalance of the gut immune system. Among them, antibody to tumor necrosis factor (anti-TNF-α) is the first developed drugs, and it dramatically improved the IBD management. However, more than one-third of the patients do not respond to the drugs due to antibody formation. To increase treatment efficacy, enormous effort to develop novel anti-cytokines which can be an alternative to anti-TNF-α has been made. They are anti CD4+ T cell cytokine including interleukin (IL)-12/23 and IL-17 blockers, selective anti-adhesion molecule known as natalizumab, vedolizumab and alicaforsen, T-cell proliferation inhibitor, anti-inflammatory cytokine,immune stimulator, growth factor, and mitogen-activated protein kinase inhibitor. The efficacy and safety of each drugs are under investigation. Some drugs reported very promising data, however, others showed disappointing and different results. In addition, most of the trials were done in a very small number of patients, and there is no trial comparing to anti-TNF-α. The present paper reviews the action mechanism, short or long term efficacy and safety of variable drugs other than anti-TNF-αin IBD.
URI
http://hdl.handle.net/YU.REPOSITORY/24253
ISSN
1598-9992
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE